The dermal sensitization threshold (DST) approach for mixtures evaluated as negative in in vitro test methods; mixture DST

• Published in: Journal of toxicological sciences Vol. 44; no. 1; pp. 23 - 34
• Main Authors: Nishijo, Taku, Miyazawa, Masaaki, Saito, Kazutoshi, Otsubo, Yuki, Mizumachi, Hideyuki, Sakaguchi, Hitoshi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Toxicology 2019; Japan Science and Technology Agency
• Subjects: Constituents; Cosmetics industry; Detection limits; Feasibility studies; h-CLAT; In vitro methods and tests; KeratinoSensTM; Lymph nodes; Mixture; Mixture DST; Risk assessment; Sensitivity; Sensitivity analysis; Sensitizing; Skin; Skin sensitization; Test methods; Mixture DST; h-CLAT; Skin sensitization; KeratinoSensTM; Mixture
• ISSN: 0388-1350; 1880-3989
• DOI: 10.2131/jts.44.23

Cosmetic ingredients often comprise complex mixtures, such as botanical extracts, which may contain skin sensitizing constituents. In our previous study for the sensitivity of the evaluations of skin sensitizing constituents in mixtures using the binary in vitro test battery with KeratinoSensTM and h-CLAT, some sensitizers showed higher detection limits in in vitro test methods than in murine local lymph node assays (LLNA). Thus, to minimize the uncertainty associated with decreased sensitivity for these sensitizers, a risk assessment strategy was developed for mixtures with negative results from the binary test battery. Assuming that the no expected sensitization induction level of mixtures (mixture NESIL) can be derived for mixtures with negative in vitro test results, we assessed 146 sensitizers with in vitro and LLNA data according to the assumption of indeterminate constituents in mixtures. Finally, we calculated 95th percentile probabilities of mixture NESILs and derived dermal sensitization thresholds for mixtures (mixture DST) with negative in vitro test results of 6010 μg/cm2. Feasibility studies indicated that this approach was practical for risk assessments of products in the cosmetic industry. This approach would be a novel risk assessment strategy for incorporating the DST approach and information from in vitro test methods.